Overview

• Sanofi will pay $129 per share to acquire Blueprint Medicines at an initial valuation of $9.1 billion that may rise to $9.5 billion upon clinical and regulatory milestones.
• The deal includes rights to Ayvakit (avapritinib), the only approved therapy for systemic mastocytosis.
• This transaction follows Sanofi’s $470 million purchase of Vigil Neuroscience on May 22 and adds a late-stage immunology asset to its pipeline.
• Previous acquisitions such as 2011’s Genzyme deal and subsequent buys of Bioverativ and Principia Biopharma illustrate a sustained rare diseases strategy.
• Sanofi states the Blueprint acquisition will not significantly affect its financial guidance for 2025.